August 17, 2010 09:08 ET

Japan to Become Key Grow Region of the Insomnia Market Over the Next 10 Years

ROCKVILLE, MD--(Marketwire - August 17, 2010) - has announced the addition of Datamonitor's new report "Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt" to their collection of Pharmaceuticals market reports. For more information, visit

In 2019, the value of the seven major insomnia markets is forecast to reach $3.5 billion. While growth of the U.S. market is set to be inhibited by further generic erosion from 2011 onwards, Japan will represent the key growth region over the next 10 years.

The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the U.S. from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 2009-2010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline.

Sanofi-Aventis's dominance in the insomnia market is under threat due to patent challenges to Ambien CR, and Datamonitor expects generic versions of this market-leading brand to enter the U.S. over the forecast period. In the absence of pipeline insomnia candidates, Sanofi-Aventis is not expected to regain its market leading status.

Three orexin receptor antagonists are currently under late stage clinical development by two Big Pharma players: GlaxoSmithKline and Merck. While safety observations raised in a Phase III trial of almorexant are of concern to developers, it has potential to become the most successful pipeline candidate.

Topics covered in the report include...

  • Analysis of insomnia epidemiology, drug recommendations, patient acquisition process and unmet medical needs.
  • In depth analysis of historic (200509) and future (201019) seven major market prescription sales dynamics.
  • Review of prescription sales data in the Rest of World (200509) and analysis of insomnia epidemiology in Brazil and China.
  • Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and country-specific sales forecasts to 2019.

For more information, visit

Contact Information